Ray Dogum
Ray Dogum is the Chief Editor of Drug Discovery Online, where he curates and leads editorial content focused on the earliest phases of drug development—from target identification and hit discovery to preclinical validation. With a background in chemical engineering and master's degrees in business and information systems from Boston University’s Questrom School of Business, Ray brings a cross-disciplinary perspective to the future of therapeutic innovation.
Ray’s career has spanned the cutting edge of healthcare and technology. At Amwell, he implemented telehealth solutions integrating medical devices and digital platforms across major US health systems. At Vibe Bio, he launched a biotech-focused podcast and newsletter, driving engagement for the company’s AI-powered pipeline analysis platform. He’s also consulted with senior pharma executives on decentralized ledger technology and led a proof-of-concept to streamline patient-centric clinical trial pre-screening.
Earlier in his career, Ray helped launch and manage a stem cell biology lab at MIT’s Koch Institute, where he supported research into the role of diet in aging and metabolic disease. Ray is also the creator and host of Health Unchained, a podcast exploring how blockchain, AI, and frontier technologies are transforming healthcare. Through in-depth interviews with researchers, entrepreneurs, and investors, he has built a resource that bridges the gap between emerging tech and real-world healthcare applications.
Passionate about enabling collaboration across disciplines, Ray is committed to helping scientists, startups, and innovators tell the stories behind their breakthroughs, shaping the conversation at the intersection of science, technology, and human health. You can often find Ray at local Boston events, staying close to the pulse on the latest discoveries and connecting with the vibrant biotech community.
Connect with Ray Dogum on LinkedIn: https://www.linkedin.com/in/raydogum/
ARTICLES BY RAY DOGUM
-
![GettyImages-1449007950]( "Can CoRegen's Treg Platform Dismantle Solid Tumors' Immune Shield?")
Can CoRegen's Treg Platform Dismantle Solid Tumors' Immune Shield?10/22/2026Backed by $93 million, CoRegen is bringing a novel Treg-engineering strategy into the clinic to test whether CRG-150 can dismantle solid tumors’ immune defenses.
-
![GettyImages-2158228359]( "Discovery & Development US 2026 - Key Notes From San Diego")
Discovery & Development US 2026 - Key Notes From San Diego10/19/2026Key takeaways from D&D US 2026 on Pfizer’s complex oncology targets, AI-enabled discovery, and the shift toward human-based NAMs.
-
![GettyImages-465024644]( "Inside Discovery On Target 2026: New Modalities, AI, And A Higher Funding Bar")
Inside Discovery On Target 2026: New Modalities, AI, And A Higher Funding Bar10/7/2026Discovery on Target 2026 showed how new modalities and AI are expanding drug discovery as investors demand stronger data and clearer paths to value.
-
![GettyImages-2229512307]( "Targeting p27 To 'Let Biology Do The Work' With Stacy Blain, CEO, Concarlo Therapeutics")
Targeting p27 To 'Let Biology Do The Work' With Stacy Blain, CEO, Concarlo Therapeutics9/29/2026Stacy Blain, PhD, turned 30 years of p27 research into Concarlo’s LOCKTAC, a molecular glue designed to restore natural CDK2/4/6 inhibition in cancer.
-
![GettyImages-1251894563]( "Bravo, FDA For Retiring 'Animal Testing' In Favor Of 'Nonclinical'")
Bravo, FDA For Retiring 'Animal Testing' In Favor Of 'Nonclinical'9/28/2026HHS is advancing human-based drug research through new FDA terminology, NIH infrastructure, CDC studies, and ARPA-H tools that reduce reliance on animal testing.
-
![GettyImages-1388153714]( "Datapoints Summit 2026 Highlights: Moving AI Closer To The Lab")
Datapoints Summit 2026 Highlights: Moving AI Closer To The Lab9/22/2026At the Datapoints Summit, speakers showed where AI can improve drug discovery—and why better data, validation, and scientific judgment remain essential for lasting progress.
-
![GettyImages-2261031243]( "What I Heard When NAMs Became a Conversation, Not a Webinar")
What I Heard When NAMs Became a Conversation, Not a Webinar9/11/2026The AAPS/BioIVT interactive event made NAM adoption feel less like a science debate and more like a trust-building exercise rooted in use cases, standards, and candid exchange.
-
![GettyImages-1226476852]( "A Simple Eye Drop For A Blinding Disease? Claris Bio Raises $118M And Prepares For Pivotal Trials")
A Simple Eye Drop For A Blinding Disease? Claris Bio Raises $118M And Prepares For Pivotal Trials9/1/2026CSB-001, Claris Bio’s eye drop for limbal stem cell deficiency, could offer a non-surgical way to improve vision, slow vision loss, and reshape LSCD care.
-
![GettyImages-2198621051]( "What The China Biotech Debate Reveals About U.S. Drug Discovery")
What The China Biotech Debate Reveals About U.S. Drug Discovery8/17/2026Peter Kolchinsky and Jason Kelly sparred over China’s biotech rise and what it means for U.S. drug discovery, investment, and strategic control.
-
![GettyImages-518355640]( "Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)")
Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)8/5/2026Rh disease has been preventable for decades. Yet babies still die worldwide because access, supply, and infrastructure have not caught up.
